1. Home
  2. ROMA vs QTTB Comparison

ROMA vs QTTB Comparison

Compare ROMA & QTTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Roma Green Finance Limited

ROMA

Roma Green Finance Limited

N/A

Current Price

$8.73

Market Cap

542.0M

Sector

Finance

ML Signal

N/A

Logo Q32 Bio Inc.

QTTB

Q32 Bio Inc.

HOLD

Current Price

$15.60

Market Cap

450.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ROMA
QTTB
Founded
2018
2015
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Savings Institutions
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
542.0M
450.1M
IPO Year
2022
2018

Fundamental Metrics

Financial Performance
Metric
ROMA
QTTB
Price
$8.73
$15.60
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$13.00
AVG Volume (30 Days)
4.6K
420.5K
Earning Date
12-23-2025
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
136.78
EPS
N/A
N/A
Revenue
N/A
$53,737,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.16
$1.62
52 Week High
$11.77
$23.57

Technical Indicators

Market Signals
Indicator
ROMA
QTTB
Relative Strength Index (RSI) 47.40 53.16
Support Level $7.56 $14.44
Resistance Level $9.75 $16.78
Average True Range (ATR) 0.53 0.87
MACD -0.09 -0.08
Stochastic Oscillator 15.52 43.57

Price Performance

Historical Comparison
ROMA
QTTB

About ROMA Roma Green Finance Limited

Roma Green Finance Ltd is a professional specialist in the provision of environmental, social and governance (ESG), sustainability and climate change related advisory services through its operating subsidiaries in Hong Kong and Singapore. Its services include Sustainability Program Development, ESG Reporting, Corporate Governance and Risk Management, Climate Change Strategies and Solutions, Environmental Audit, ESG Rating Support and Shareholder Communication, and Education and Training. It operates in one reporting business segment in Hong Kong and Singapore, of which the majority of revenue is derived from Hong Kong.

About QTTB Q32 Bio Inc.

Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).

Share on Social Networks: